These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 25536109)

  • 1. Current nanotechnology approaches for the treatment and management of diabetic retinopathy.
    Fangueiro JF; Silva AM; Garcia ML; Souto EB
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):307-22. PubMed ID: 25536109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current treatment strategies and nanocarrier based approaches for the treatment and management of diabetic retinopathy.
    Selvaraj K; Gowthamarajan K; Karri VV; Barauah UK; Ravisankar V; Jojo GM
    J Drug Target; 2017 Jun; 25(5):386-405. PubMed ID: 28122462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanotechnology in ocular delivery: current and future directions.
    Sultana Y; Maurya DP; Iqbal Z; Aqil M
    Drugs Today (Barc); 2011 Jun; 47(6):441-55. PubMed ID: 21695286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.
    Kompella UB; Amrite AC; Pacha Ravi R; Durazo SA
    Prog Retin Eye Res; 2013 Sep; 36():172-98. PubMed ID: 23603534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress of Nanotechnology in Diabetic Retinopathy Treatment.
    Liu Y; Wu N
    Int J Nanomedicine; 2021; 16():1391-1403. PubMed ID: 33658779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic stratagems for vascular degenerative disorders of the posterior eye.
    Jain GK; Warsi MH; Nirmal J; Garg V; Pathan SA; Ahmad FJ; Khar RK
    Drug Discov Today; 2012 Jul; 17(13-14):748-59. PubMed ID: 22504325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent trends in drug-delivery systems for the treatment of diabetic retinopathy and associated fibrosis.
    Silva M; Peng T; Zhao X; Li S; Farhan M; Zheng W
    Adv Drug Deliv Rev; 2021 Jun; 173():439-460. PubMed ID: 33857553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetic retinopathy: current management and experimental therapeutic targets.
    Ali TK; El-Remessy AB
    Pharmacotherapy; 2009 Feb; 29(2):182-92. PubMed ID: 19170588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microspheres and Nanotechnology for Drug Delivery.
    Jóhannesson G; Stefánsson E; Loftsson T
    Dev Ophthalmol; 2016; 55():93-103. PubMed ID: 26501994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of doxycycline vs placebo on retinal function and diabetic retinopathy progression in patients with severe nonproliferative or non-high-risk proliferative diabetic retinopathy: a randomized clinical trial.
    Scott IU; Jackson GR; Quillen DA; Larsen M; Klein R; Liao J; Holfort S; Munch IC; Gardner TW
    JAMA Ophthalmol; 2014 May; 132(5):535-43. PubMed ID: 24604308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Updates on Nanocarriers for Drug Delivery in Posterior Segment Diseases with Emphasis on Diabetic Retinopathy.
    Parashar R; Vyas A; Sah AK; Hemnani N; Thangaraju P; Suresh PK
    Curr Diabetes Rev; 2024; 20(6):e171023222282. PubMed ID: 37855359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opening eyes to nanomedicine: Where we are, challenges and expectations on nanotherapy for diabetic retinopathy.
    Campos EJ; Campos A; Martins J; Ambrósio AF
    Nanomedicine; 2017 Aug; 13(6):2101-2113. PubMed ID: 28428052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases.
    Wu Y; Li X; Fu X; Huang X; Zhang S; Zhao N; Ma X; Saiding Q; Yang M; Tao W; Zhou X; Huang J
    Adv Sci (Weinh); 2024 Aug; 11(32):e2403399. PubMed ID: 39031809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug, delivery and devices for diabetic retinopathy (3Ds in DR).
    Nirmal J; Radhakrishnan K; Moreno M; Natarajan JV; Laude A; Lim TH; Venkatraman S; Agrawal R
    Expert Opin Drug Deliv; 2016 Nov; 13(11):1625-1637. PubMed ID: 27169870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basic and clinical aspects of gene therapy for retinopathy induced by diabetes.
    Ting JH; Martin DK
    Curr Gene Ther; 2006 Apr; 6(2):193-214. PubMed ID: 16611042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic retinopathy: neuron protection as a therapeutic target.
    Zhang X; Wang N; Barile GR; Bao S; Gillies M
    Int J Biochem Cell Biol; 2013 Jul; 45(7):1525-9. PubMed ID: 23506699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanocarriers for treatment of ocular neovascularization in the back of the eye: new vehicles for ophthalmic drug delivery.
    Shen HH; Chan EC; Lee JH; Bee YS; Lin TW; Dusting GJ; Liu GS
    Nanomedicine (Lond); 2015; 10(13):2093-107. PubMed ID: 26096379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanotechnology in ocular drug delivery.
    Sahoo SK; Dilnawaz F; Krishnakumar S
    Drug Discov Today; 2008 Feb; 13(3-4):144-51. PubMed ID: 18275912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticle-Mediated Delivery of Neuroprotective Substances for the Treatment of Diabetic Retinopathy.
    Amato R; Dal Monte M; Lulli M; Raffa V; Casini G
    Curr Neuropharmacol; 2018; 16(7):993-1003. PubMed ID: 28714394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in intraocular and novel drug delivery systems for the treatment of diabetic retinopathy.
    Sharma DS; Wadhwa S; Gulati M; Kadukkattil Ramanunny A; Awasthi A; Singh SK; Khursheed R; Corrie L; Chitranshi N; Gupta VK; Vishwas S
    Expert Opin Drug Deliv; 2021 May; 18(5):553-576. PubMed ID: 33143473
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.